- Published on
This Once-Daily Pill Helps The Skin Regain Its Color in People With Vitiligo
- Authors
- Name
- DeepHorus
A once-daily pill has demonstrated significant success in restoring skin color for people living with vitiligo, offering a promising new treatment path for a condition that affects millions worldwide. The development provides a systemic option, particularly beneficial for those with widespread patches or areas difficult to treat with topical creams. Unlike localized therapies, the oral medication works throughout the body, addressing the condition's root cause.
Vitiligo is an autoimmune disorder where the body's immune system mistakenly attacks melanocytes, the cells responsible for skin pigment. This leads to the characteristic white patches. The condition, while not contagious, often carries a significant psychological burden, leading to stigma, anxiety, and social exclusion for those affected. Therefore, treatment aims to improve both physical appearance and quality of life.
Existing treatments like topical steroids and light therapy can be effective but often require prolonged, frequent application or clinic visits, which can be challenging for extensive vitiligo. The new therapy offers a more convenient, systemic approach. A major clinical trial, published in The Lancet, evaluated the drug upadacitinib in 614 participants aged 12 and older across 18 countries.
In the double-blind study, participants received either 15mg of upadacitinib or a placebo daily for 48 weeks. The results were striking. In one trial, 25% of patients on the drug regained at least 75% of color on their face, compared to just 6% on placebo. Similar efficacy was seen in the second trial, with 23% versus 7% reaching the same goal.
The benefits extended beyond the face. Across both trials, approximately 20% of treated patients recovered at least half of the lost color on their bodies, versus only 6% on placebo. Furthermore, 14% of those on upadacitinib regained at least 90% of facial color, a notable improvement over the placebo group. Importantly, color continued to return at the trial's end, suggesting longer treatment may yield greater benefits.
Upadacitinib belongs to the JAK inhibitor class of drugs, which work by modulating the immune response. By calming the specific pathway that attacks melanocytes, the drug may allow skin cells to recover pigment. This mechanism makes it a valuable option for widespread vitiligo where topical treatments are impractical.
Despite the positive outcomes, limitations remain. About three-quarters of patients on the drug did not meet the primary endpoint for facial repigmentation. The most common side effects were upper respiratory infections, acne, and headaches. Seven patients on upadacitinib developed shingles. The drug also carries existing warnings for serious infections, cardiovascular events, and malignancies.
Upadacitinib is now approved in the European Union for eligible vitiligo patients aged 12 and older. Approval in other regions is pending. Continued follow-up of trial participants is underway to monitor long-term safety and efficacy, as the 48-week study period could not assess very rare or delayed risks.
